DNTH stock forecast, quote, news & analysis
Dianthus Therapeutics Inc... Show more
Why Dianthus Therapeutics (DNTH) Is Up +18% in the Last 30 Days
Key Takeaways
- Dianthus Therapeutics (DNTH) stock rose +18% over the past 30 days, driven by positive clinical trial updates and analyst enthusiasm for its lead complement inhibitor.
- Over the past quarter, shares surged +111%, fueled by a major upsized public offering and an early "go" decision in the Phase 3 CAPTIVATE trial for chronic inflammatory demyelinating polyneuropathy (CIDP).
- Key catalysts include a $719 million equity raise, progress in claseprubart development, and bullish analyst targets averaging above $125.
- Biotech sector sentiment and institutional interest have supported the upward momentum amid favorable trial readouts.
- Investors should monitor upcoming Phase 3 milestones and macroeconomic conditions affecting biotech funding.
Dianthus Therapeutics (DNTH) Company Overview and Market Position
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation complement antibody therapeutics for patients with severe autoimmune diseases. Its lead candidate, claseprubart, targets the classical complement pathway with high selectivity, aiming to address unmet needs in conditions like CIDP and generalized myasthenia gravis (gMG). The company's business model centers on advancing monoclonal antibodies through clinical trials toward commercialization, leveraging partnerships and internal R&D. In the competitive biotech landscape, Dianthus differentiates through its precision-engineered antibodies, positioning it well amid growing demand for targeted immunomodulators. Strong cash position post-fundraise bolsters its runway, explaining resilience in recent stock price movements despite clinical-stage risks.
Dianthus Therapeutics (DNTH) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, DNTH stock climbed from $78.86 to $92.90, marking a +18% gain. The movement was trend-driven with moderate volatility, peaking near $96 before a slight pullback.
In the past quarter, shares advanced from $44.00 to $92.90, delivering a +111% increase. Performance was volatile yet upward, with a notable dip to $36.20 early in the period followed by sharp recoveries on positive news, reflecting range-bound action before breaking higher.
What Drove DNTH Stock Price in the Last 30 Days
DNTH's 30-day uptick built on March momentum, with analyst upgrades reinforcing gains. Wedbush maintained Outperform, highlighting claseprubart's potential in CIDP, while Wolfe Research initiated Outperform at $98 and Guggenheim reiterated Buy. These notes spurred buying amid broader biotech optimism. A 5.6% single-session jump to $83.92 reflected solid volume and strength in trading. Insider activity, including CFO share sales, introduced minor pressure, but positive sentiment from early Phase 3 progress overshadowed it. Sector tailwinds in immunology further supported the steady climb in stock price.
What Drove DNTH Stock Performance Over the Last Quarter
The quarter's +111% rally stemmed from transformative events, including an upsized $625 million public offering priced at $81 per share, closing at $719 million after full exercise of the underwriters' option. This bolstered cash reserves for trials, alleviating dilution fears and signaling confidence. Catalyzing the surge was the early "go" decision in the CAPTIVATE Phase 3 CIDP trial for claseprubart, dropping the 600 mg arm for efficiency and advancing topline data timelines. Q4 earnings, despite an EPS miss at -$1.43, highlighted pipeline momentum, driving post-report gains. Analyst upgrades and biotech market trends amplified institutional flows, with macroeconomic easing in rates aiding funding access. These factors cumulatively propelled DNTH from quarterly lows, underscoring trial and financing as dominant drivers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from a library of hundreds that analyze and trade thousands of tickers across various markets. These curated bots employ diverse strategies, such as trend-following, mean reversion, or momentum plays, across short-term, swing, or long-term timeframes. Performance metrics like win rate, profit factor, and Sharpe ratio help users gauge effectiveness, with filters for relevance to specific stocks like DNTH or biotech sectors. Updated in real-time, the section highlights bots excelling in current market conditions, offering investors data-backed automation tools. Explore the page to identify bots aligning with your trading style and enhance your portfolio strategy.
DNTH Stock Forecast Drivers: What Investors Should Watch Next
Investors should track progress in the CAPTIVATE Phase 3 CIDP trial, including interim data and enrollment updates for claseprubart. Upcoming pivotal trial initiation for gMG in mid-2026 represents a key milestone. Monitor analyst revisions amid evolving trial outcomes and peer developments in complement therapeutics. Macro factors like interest rates and biotech M&A (mergers and acquisitions) activity could influence sentiment. Regulatory feedback from the FDA on trial designs and cash burn rates post-fundraise warrant attention. Potential partnerships or competitive readouts in autoimmune therapies pose both risks and catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Momentum Indicator for DNTH turns positive, indicating new upward trend
DNTH saw its Momentum Indicator move above the 0 level on June 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned positive. In of the 98 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for DNTH just turned positive on June 22, 2026. Looking at past instances where DNTH's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
DNTH moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DNTH advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .
DNTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for DNTH crossed bearishly below the 50-day moving average on June 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNTH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for DNTH entered a downward trend on May 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DNTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.976) is normal, around the industry mean (20.966). P/E Ratio (3.238) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). DNTH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). DNTH's P/S Ratio (2500.000) is slightly higher than the industry average of (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology